Immunotherapy cocktail takes on tough pancreatic cancer

NCT ID NCT06050317

Recruiting now Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding the immunotherapy drug sintilimab to chemotherapy and radiation can help people with inoperable pancreatic cancer live longer. The study will enroll 25 participants who have not had prior treatment. Researchers will track how long the cancer stays under control and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab (an immunotherapy drug) plus chemotherapy (mFFN or NALIRIFOX) and radiation
What this could lead to: If it works, this could offer a new treatment option to control inoperable pancreatic cancer and extend survival.
What could go wrong: This is a small, early-phase trial with only 25 people, so results may not apply widely. Side effects from the combination therapy could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREAS CANCER

Contacts and locations

Locations

Department of Radiation Oncology, Shandong Cancer Hospital and Institute
RECRUITING

Jinan, Shandong, 0531, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.